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Kinesin spindle protein inhibition is known to be an effective ther-apeutic approach in several malignancies. Filanesib (ARRY-520), aninhibitor of this protein, has demonstrated activity in heavily pre-
treated multiple myeloma patients. The aim of the work herein was to
investigate the activity of filanesib in combination with pomalidomide
plus dexamethasone backbone, and the mechanisms underlying the
potential synergistic effect.The ability of filanesib to enhance the activity
of pomalidomide plus dexamethasone was studied in several in vitro and
in vivomodels. Mechanisms of this synergistic combination were dissect-
ed by gene expression profiling, immunostaining, cell cycle and short
interfering ribonucleic acid studies. Filanesib showed in vitro, ex vivo, and
in vivo synergy with pomalidomide plus dexamethasone treatment.
Importantly, the in vivo synergy observed in this combination was more
evident in large, highly proliferative tumors, and was shown to be medi-
ated by the impairment of mitosis transcriptional control, an increase in
monopolar spindles, cell cycle arrest and the induction of apoptosis in
cells in proliferative phases. In addition, the triple combination increased
the activation of the proapoptotic protein BAX, which has previously
been associated with sensitivity to filanesib, and could potentially be
used as a predictive biomarker of response to this combination. Our
results provide preclinical evidence for the potential benefit of the com-
bination of filanesib with pomalidomide and dexamethasone, and sup-
ported the initiation of a recently activated trial being conducted by the
Spanish Myeloma group which is investigating this combination in
relapsed myeloma patients.
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ABSTRACT
Introduction
The use of novel agents has resulted in a clear improvement in the survival of
multiple myeloma (MM) patients. However, most patients eventually relapse,1
denoting the need for new drugs targeting key pathogenic mechanisms of the
tumor plasma cell.2 CYCLIN D deregulation is a common oncogenic event found
in 98% of MM patients,3 and considerable effort has been expended in trying to
identify agents targeting the cell cycle of myeloma cells. Examples of such mole-
cules are seliciclib (an inhibitor of CDK4/CDK6)4 and AURORA KINASE
inhibitors.5 Unfortunately, thus far these agents have not proved to be sufficiently
effective or were stopped due to toxicity6 in myeloma patients, who subsequently
continued MM disease development. 
Filanesib (ARRY-520), a first-in-class7 kinesin spindle protein (KSP) inhibitor, is a
novel agent targeting this same pathogenic area.8 KSP (EG5/KIF11) is a member of
the mitotic kinesin family that is only expressed in dividing cells9 and is essential
for establishing the mitotic bipolar spindle and ensuring centrosome separation.10
Inhibition of KSP activity arrests cells in metaphase by
forming aberrant monopolar spindles and impairing the
separation of centrosomes.11 The activity of filanesib is
determined by two main factors: first, the integrity of
components of the spindle checkpoint, which arrests cells
when an alteration in mitosis is found, and second, the
loss of anti-apoptotic signals12 during mitotic blockade,
particularly the decrease in the MCL-1 protein.13 This lat-
ter protein is essential for the survival of MM cells,13,14
therefore, myeloma cells might be particularly susceptible
to filanesib treatment.12 This agent has already been
explored in MM in a phase II clinical trial, in which it gave
a 16% response rate (≥partial response (PR)) in heavily
treated patients who had received all available agents and
a median of six previous lines of therapy.7 This initial
activity prompted the search for potential combinations
that could enhance the activity of the current backbones
of therapy in relapsed MM.
In this context, pomalidomide in combination with dex-
amethasone induces a 30% overall response rate and pro-
longs overall survival by up to one year in patients already
exposed to immunomodulatory drugs (IMiDs) and protea-
some inhibitors and refractory to the last line of thera-
py.15,16 However, novel partners for combination with this
doublet are currently being sought, with the aim of
improving these results.
In the present study we evaluated the preclinical anti-
myeloma activity of the triple combination of pomalido-
mide+dexamethasone+filanesib (PDF). Preliminary data
reported synergy of filanesib with pomalidomide in a
xenograft mouse model.17
Herein, we demonstrate that filanesib is a good partner
for combination with all IMiDs plus dexamethasone, the
combination with pomalidomide being particularly potent
in the dexamethasone sensitive MM.1S cell line, and very
effective in a large panel of other MM cell lines. This syner-
gistic effect is partly mediated by an increase in monopolar
spindle formation and the simultaneous upregulated
expression and activation of the proapoptotic protein BAX
in actively proliferating myeloma cells. These findings sup-
ported the ongoing clinical trial (clinicaltrials.gov Identifier:
02384083) conducted by the Spanish MM group to evaluate
the safety and efficacy of this triple combination in
relapsed/refractory MM patients.
Methods
(For more specific information see the Online
Supplementary File)
Reagents and drugs
Filanesib was provided by Array BioPharma Inc. (Boulder, CO,
USA). Thalidomide, lenalidomide and pomalidomide were pur-
chased from Selleckchem (Houston, TX, USA), dexamethasone
from Sigma-Aldrich (St Louis, MO, USA) and bortezomib from
LC Laboratories (Woburn, MA, USA).
MM cell lines, patient samples and cultures
Origin, authentication and in vitro growth conditions of MM cell
lines have already been characterized.18,19 The study of the activity
in the presence of interleukin (IL)-6, insulin-like growth factor
(IGF)-1 or co-culture with stroma was performed as described.20,21
Bone marrow (BM) samples from MM patients were obtained fol-
lowing institutional approval and written informed consent.
Cell viability, cell cycle and apoptosis assays
Cell viability of MM cells was evaluated by the MTT assay.22
The cell cycle profile, apoptosis induction and mitochondrial
membrane potential was analyzed by flow as described.21 In vitro
synergism was quantitated using CalcuSyn software23 (Biosoft,
Ferguson, MO, USA) via a constant ratio drug combination design.
Ex vivo analysis of apoptosis in freshly isolated patient cells.
Cytometry analyses of apoptosis in BM tumor plasma cells and
lymphocytes were performed as described.24
Immunofluorescence study
MM.1S cells treated for 24h were fixed, blocked and incubated
overnight with a primary anti-α-tubulin antibody (Sigma) and
counterstained with Alexa Fluor 488 conjugated anti-mouse
immunoglobulin G (IgG) secondary antibody (Life Technologies,
Waltham, MA, USA) and a 4',6-Diamidino-2-Phenylindole,
Dihydrochloride (DAPI) solution (Sigma). 
Western blot
All procedures were performed as described.24 All antibodies
were purchased from Cell Signaling Technology (Boston, MA,
USA) except for anti-MCL-1 (Santa Cruz Biotechnology. Santa
Cruz, CA, USA), anti-CYTOCHROME C (Calbiochem, Billerica,
MA, USA) and Horseradish peroxidase-conjugated secondary
antibodies (GE Healthcare. Little Chalfont, UK).
Gene silencing with siRNA
MM.1S cells were transiently transfected with either 100 nM
non-targeting control short interfering RNA (NT-siRNA) or 100
nM ON TARGET plus SMART pool siRNA targeting human BAX
(BAX-siRNA; Dharmacon, Lafayette, CO, USA) using the
Nucleofector II system (Lonza, Allendale, NJ, USA). 
Animal models
The human subcutaneous plasmacytoma model in CB17-
severe combined immunodeficiency (SCID) mice (The Jackson
Laboratory, Bar Harbor, ME, USA) was used as described.21,25
Animal experiments were conducted with permission from the
local Ethical Committee for Animal Experimentation.
Histological and immunohistochemistry (IHC) analyses
This technique has been previously described25 using an anti-
BAX antibody (Cell Signaling, Boston, MA, USA) and the
EnVision anti-mouse/rabbit peroxidase complexes (Dako,
Glostrup, Denmark). Peroxidase activity was identified using the
3,3′-diaminobenzidine MAPO system (Ventana Medical Systems,
Roche, Tucson, AZ, USA). Sections were counterstained with
hematoxylin and analyzed by standard light microscopy. 
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) was performed using the In Situ Cell Death Detection Kit
(Roche, Mannheim, Germany). Sections were counterstained with
DAPI and visualized by confocal laser microscopy (Leica TCS SP2).
RNA isolation, cDNA synthesis and microarray
hybridization and analysis
Tumors and MM.1S cells (n=3 for each treatment) were
hybridized in Human Gene 2.0 ST arrays (Affymetrix) following
manufacturer's instructions. The raw intensity data were pre-
processed using the RMA algorithm26 implemented in the
Affymetrix Expression Console, version 1.4.1.46. Differentially
expressed genes were identified using the significance analysis of
microarrays (SAM) algorithm,27 version 4.01, selecting genes with
q value <0.05. Microarray data are available in the Gene
Expression Omnibus (GEO) repository database (Accession num-
ber GSE94341). 
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Table 1. The most significant biological processes which were deregulated with the treatments.
In vitro PD F PDF 
Adjusted Genes Adjusted Genes Adjusted Genes
P in GO P in GO P in GO 
dataset dataset dataset 
Biological Processes Common to PD, F, and PDF
mitotic cell cycle process 1.85E-19 258 3.55E+00 3 5.18E-27 283
mitotic cell cycle phase transition 5.29E-15 162 1.19E+00 3 1.59E-15 166
cell cycle phase transition 1.35E-14 168 1.34E+00 3 4.80E-15 172
Biological Processes Common  to PD and PDF
ncRNA metabolic process 2.72E-30 211 - - 3.45E-23 199
RNA processing 8.19E-31 293 - - 1.10E-21 274
rRNA processing 9.22E-21 114 - - 2.66E-19 113
DNA replication 1.98E-24 126 - - 6.87E-19 118
DNA metabolic process 4.04E-22 290 - - 4.25E-15 273
Biological Processes Exclusive to PD
protein targeting 6.36E-03 162 - - - -
regulation of DNA recombination 7.51E-03 26 - - - -
mRNA-containing ribonucleoprotein. complex export from nucleus 1.66E-02 36 - - - -
mRNA export from nucleus 1.66E-02 36 - - - -
DNA replication checkpoint 1.96E-02 12 - - - -
Biological Processes Exclusive to PDF 
mitotic sister chromatid segregation - - - - 9.07E-06 53
nuclear chromosome segregation - - - - 2.43E-04 84
metaphase plate congression - - - - 7.02E-03 23
mitotic metaphase plate congression - - - - 1.33E-02 19
establishment of chromosome localization - - - - 1.96E-02 28
In vivo PD F PDF 
Adjusted Genes Adjusted Genes Adjusted Genes
P in GO P in GO P in GO
dataset dataset dataset
Biological Processes Common to PD and PDF
mitotic cell cycle process 2.45E+00 13 3.34E-02 20
Biological Processes exclusive to PD
G1/S transition of mitotic cell cycle 2.11E-03 8 - - - -
regulation of peptidase activity 1.44E-02 9 - - - -
integrin-mediated signaling pathway 3.23E-02 5 - - - -
regulation of cell protein metab. process  4.19E-02 23 - - - -
regulation of protein metab. process 4.34E-02 24 - - - -
Biological Processes exclusive to PDF
nuclear division - - - - 4.02E-05 21
cell migration - - - - 3.67E-03 27
sterol biosynthetic process - - - - 3.95E-03 6
secondary alcohol metab. proc. - - - - 4.17E-03 8
sterol metabolic process - - - - 6.80E-03 8
mitotic nuclear division - - - - 9.05E-03 14
regulation of nervous system - - - - 9.91E-03 20
alcohol biosynthetic process - - - - 1.17E-02 7
mitotic cell cycle phase transition - - - - 1.42E-02 15
nervous system development - - - - 1.65E-02 39
brain development - - - - 2.00E-02 18
cholesterol metabolic process - - - - 2.08E-02 7
regulation of viral gen. replic. - - - - 2.40E-02 6
cell cycle phase transition - - - - 2.48E-02 15
regulation of nuclear division - - - - 2.56E-02 8
metaphase plate congression - - - - 2.73E-02 5
animal organ development - - - - 3.22E-02 50
List of the most significant ontological categories of biological processes (level 5 in the GO classification) in functional enrichment analysis (DAVID) for deregulated genes in
either MM.1S cells or mouse tumors treated with PD, F and PDF.  The number of deregulated genes for each treatment is represented in  Venn diagrams (Figure 2C, D). Terms of
the significant biological processes, Benjamini–Hochberg adjusted P-value, and the number of genes present in each category are shown. Biological processes related to mitosis
are shaded in blue. PD: pomalidomide+dexamethasone; F: filanesib; PDF: pomalidomide+dexamethasone+filanesib; GO: Gene Ontology; RNA: ribonucleic acid; G1/S: Gap 1/syn-
thesis.
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Figure 1. IMiDs, especially pomalidomide and dexamethasone, strongly synergized with filanesib. A) Cell viability of MM.1S cells treated with F plus TD, LD, PD, or
the triple combination for 48h. Results are shown as the percentage of control. Data are summarized as the mean ± SD (n=3). Combination indexes (CI) for the com-
bination of filanesib and each of the IMiDs together with dexamethasone are shown in Online Supplementary Figure S1B & S1D. Tumor growth curves of SCID mice
randomized and treated when their tumors became palpable (B; small plasmocytomas; mean volume around 125 mm3; range 30 - 237; n=6 per group) or reached
a substantial volume (D; large plasmacytomas; mean volume around 2500 mm3; range 1617 - 3134; n=3 per group) at the moment of treatment initiation.
Experimental groups included: C (vehicle control; intraperitoneal injection (i.p.) 5 days per week), F (10 mg/kg i.p., 2 days per week), D (0.5 mg/kg i.p., 2 days per
week), T (50 mg/kg i.p., 5 days per week), L (25 mg/kg i.p., 5 days per week), and P (8 mg/kg i.p., 5 days per week) in monotherapy or in double or triple combination.
Data are summarized as the mean ± SEM. C & E) Analysis of survival by Kaplan-Meier estimator from mice with (C) small or (E) large tumors. F) BM cells from 9 MM
patients incubated with P 500 nM, D 10 nM and F 1 nM alone and in the different combinations for 48h. Apoptosis induction was analyzed by Annexin-V staining
by flow cytometry assay, both in plasma cells and lymphocytes that were identified based on the surface expression of CD38 and CD45, respectively. A statistically
significant difference (P<0.05) was found between plasma cells treated with PDF and control. Error bars indicate the last “non-outlier” value at each side. F: filanesib;






Statistical analyses were performed with IBM SPSS Statistics
v.21.0 (IBM Corp., Armonk, NY, USA).
Results
Filanesib potentiates the anti-myeloma activity of
pomalidomide in combination with dexamethasone
Firstly, the ability of filanesib (F) to enhance the activity
of the different IMiDs in combination with dexametha-
sone (D) was evaluated. MM.1S cells were treated for 48h
with different doses of thalidomide + dexamethasone
(TD), lenalidomide + dexamethasone (LD) or pomalido-
mide + dexamethasone (PD), with or without different
concentrations of filanesib, and viability was analyzed by
MTT  assay (Figure 1A). All IMiDs + dexamethasone had
a synergistic effect with filanesib, with combination
indexes (CIs) in the synergistic range (most synergic CIs of
0.112, 0.103, and 0.063 for TDF, LDF and PDF, respective-
ly; Online Supplementary Figure S1). However, the most
effective combination was that of F with PD (Figure 1A). 
This potentiation was also maintained in vivo in a subcu-
taneous plasmacytoma model, as filanesib enhanced the
effect of TD, LD and PD in terms of delay in tumor
growth (Figure 1B). In this regard, the PDF combination
was particularly potent, as the addition of low doses of
filanesib significantly reduced the mean tumor volume
from day 26 of treatment compared with the standard of
care PD. Moreover, the triple combination of PDF com-
pletely controlled tumor growth for up to 50 days. PDF
was also superior to the other two tested combinations,
TDF and LDF (Student´s t-test, P<0.05, from days 8 and
10 of treatment, respectively). The tumor growth control
observed with PDF translated into a statistically significant
improvement in the survival of treated mice, with a medi-
an survival (CI 95%) of 74 (71-76) days for PDF compared
with 56 (55-61) days for mice treated with the standard
backbone PD (log-rank test, P=0.004; Figure 1C). The sur-
vival analysis also favored PDF over the other IMiD com-
Filanesib, pomalidomide and dexamethasone in MM
haematologica | 2017; 102(12) 2117
Figure 2. Effect of PD, F and PDF treatments on gene expression profiles. A & B) Venn diagrams of significantly deregulated genes in MM.1S cells (A) or tumors
from mice (B) after treatment with PD, F and PDF vs. control. C & D) Venn diagrams of the biological processes (Gene Ontology at level 5) deregulated by the PD, F
and PDF treatments vs. control in in vitro (C) and in vivo (D) studies. A list of the most significant biological processes deregulated in the in vitro and in vivo studies
is shown in Table 1; only processes from level 5 Gene Ontology categories (the most specific processes) were considered, in order to avoid redundancy. P: pomalido-
mide; D: dexamethasone; F: filanesib; C: control.
A B
C D
binations (log-rank test, P<0.001 for PDF compared with
TDF and LDF; Figure 1C). As filanesib exerts its activity on
dividing cells, the PDF combination could be particularly
active in highly proliferative cells. Therefore, we assessed
the effect of PDF on mice bearing large plasmacytomas
growing in the exponential phase. PDF was able to control
these rapidly progressing tumors (Figure 1D), and there
was also a statistically significant advantage with respect
to the reduction of tumor volume compared with filanesib
in monotherapy from day 15, and from day 5 when com-
pared with the PD double combination (Student’s t-test,
P<0.05). As shown in Figure 1E, there was a noticeable
improvement in median survival (CI 95%), from 14 (11-
17) and 18 (18-18) days for PD and F, respectively, to 59
S. Hernández-García et al.
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Figure 3. PDF boosted the formation of monopolar spindles A) Quantitative determination of monopolar spindles in MM.1S cells treated with the vehicle (control),
PD, F or PDF for 24h. Representative micrographs showing cells immunostained with anti-tubulin antibody (shown in green) to visualize microtubules and DAPI (blue)
to evidence nuclei using confocal microcopy. Bar = 15 mm in lower magnification micrograph; bar = 5 mm in higher magnification insert). Data are presented as the
mean ± SD of two independent experiments. Statistical significance was evaluated with Student’s t-test. B) Evaluation of monopolar spindles in paraffin sections of
tumors from mice treated with vehicle (control=C), PD, F or PDF for two days and stained with hematoxylin and eosin (H&E). Thirty high-power fields (600x) were
evaluated for each experimental condition (3 mice per condition). Monopolar spindles were characterized by chromosomes stained with hematoxylin (in purple) ori-
entated in a ring. Bar = 10 μm). Data are presented as the mean ± SD. Statistical significance was evaluated with Student’s t-test. P: pomalidomide; D: dexametha-
sone; F: filanesib.
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Figure 4. PDF triggered cell cycle arrest and apoptosis of MM cells in pro-liferative phases.  (A) Analysis of cell cycle by flow cytometry in MM.1S cells treated with
the vehicle (control=C), PD, F or PDF for 48h after Draq5 staining (Draq5 binds to DNA from both living and non-living cells). B) Simultaneous analysis of cell cycle
profile and apoptosis induction in MM.1S cells treated with C, PD, F or PDF for 48h by flow cytometry after Draq5/Annexin-V staining. C) Percentage of apoptotic cells
in each phase of the cell cycle was also calculated. Data shown is for a representative experiment that was repeated at least twice. D) Western blot analysis of cell
cycle proteins CYCLIN B1, phosphorylated HH3 and PARP in MM.1S cells treated with indicated conditions for 12h to 48h. E) Apoptosis induction in MM.1S cells treat-
ed with C, PD, F or PDF for 48h and analyzed by flow cytometry after staining with Annexin-V. F) Micrographs of tumor sections from mice treated for two days with
C, PD, F or PDF and histochemically stained with TUNEL assay. Quantitative determination of TUNEL-positive cells (30 630x fields per experimental condition, 3 mice






(45-73) days for animals treated with PDF (log-rank test,
P<0.05 for all comparisons). It is remarkable that PDF was
able to improve the survival of these end-stage mice by
almost two months. With regard to toxicity, the PDF triple
combination was well tolerated by mice in the initial
experiment, and the effect was not worse than that of PD
alone. In mice with large plasmacytomas, treatment
induced a moderate decrease in body weight (not reaching
20%), which was recovered on the days without treat-
ment, and which was partly due to the poor clinical con-
dition of the mice (Online Supplementary Figure S2). 
Based on this data and the fact that the combination
with pomalidomide and dexamethasone is particularly
appealing in the clinical setting, we decided to expand our
study of this combination in MM. First, its synergy was
evaluated in some additional MM cell lines; MM144, JJN3,
RPMI8226-LR5 and OPM-2; showing CIs in the synergis-
tic range (Online Supplementary Figure S3). The potent anti-
myeloma effect of the PDF triple combination was main-
tained in the presence of IGF-1 or IL-6, two important fac-
tors in the myeloma BM microenvironment. Additionally,
the PDF combination was also effective when the MM.1S
cells were co-cultured with either human mesenchymal
stromal cells from myeloma patients (BMSCs) or the
human mesenchymal stromal line (hMSC-TERT) (Online
Supplementary Figure S4).
The effect of PDF was further evaluated ex vivo in BM
aspirates of nine MM patients. Both filanesib alone as well
as pomalidomide and dexamethasone were active in these
patients. However, only the triple combination demon-
strated a statistically significant difference when com-
pared with the control (C) untreated cells (PDF vs. C,
P=0.04; Figure 1F). Moreover, there was a clear therapeutic
window, as the toxicity on the lymphocytes of these same
patients was clearly lower.
It is of note that although the efficacy of the triple com-
bination PDF was observed in vitro in several MM cell lines
as well as in patients samples, its benefit over LDF or TDF
was only explored in a single cell line. 
The PDF combination deregulates genes necessary 
for mitosis 
In order to investigate the mechanism of action of the
triple combination, changes induced by the different treat-
ments in the gene expression profiles of MM.1S cells in
vitro or in tumors from treated mice were analyzed and
compared with their respective untreated controls. In both
studies, whereas filanesib alone induced a minimal
genomic deregulation with respect to the control (6 and 4
genes significantly deregulated in the in vitro and in vivo
experiments, respectively), treatment with PDF enhanced
the effect of PD, particularly in the in vivo study (3460 vs.
3317 and 238 vs. 141 deregulated genes in the in vitro and
in vivo studies, respectively; Figure 2A,B. See Online
Supplementary Table S1 and Table S2 for differentially
deregulated genes in the PDF combination in vitro and 
in vivo, respectively. A complete list of the 3460 genes
deregulated in vitro is also provided as a supplement). Due
to the variety of functions in which these genes were
involved, a functional enrichment analysis was performed
in order to identify the biological processes most signifi-
cantly affected by the deregulated genes following expo-
sure to PD, F and PDF treatments in both experiments (see
Table 1 and Venn diagrams for biological processes in
Figure 2C,D). Three biological processes were commonly
deregulated by all treatments in the in vitro experiments
(while no common process was discovered in the in vivo
experiment), and all of them were related to mitosis and
cell cycles (Table 1). Of interest, the top five biological
processes exclusively deregulated in the PDF combination
in vitro were involved in different stages of mitosis; in line
with this, five out of the 17 biological processes uniquely
altered in the PDF treatment in vivo were also associated
with mitosis and nuclear division (see shaded processes in
Table 1). 
Next, we selected those genes deregulated in the triple
combination in vitro which were involved in mitotic and
cell cycle processes (Online Supplementary Table S3). Of
note, CCNB1 and CCNB2, encoding for B-type cyclins
and being major regulators of the G2/M transition of cell
cycle, are upregulated in the PDF treatment. The upregu-
lated expression of PSMD3, a 26S proteasome subunit,
and NEK2, involved in the anaphase promoting complex
and centrosomal separation, may also be mediating the
increased mitotic and cell cycle progression processes in
this combination. Similarly, CDC25C and CDC25B,
required for entry into mitosis, show an increased expres-
sion in the PDF combination.
The PDF combination enhances the formation of 
aberrant monopolar spindles
One mechanism underlying the synergy of the triple
combination could be the enhancement of the ability of
filanesib to block mitosis and to induce monopolar spin-
dles, the characteristic sequelae of KSP inhibition. To test
this hypothesis, the formation of aberrant monopolar
spindles was evaluated after a 24h treatment of MM.1S
cells with vehicle, F, PD or PDF. Whereas the majority of
untreated cells and those exposed to PD displayed normal
mitoses with typical bipolar spindles, almost all F- and
PDF-treated cells that were in mitosis showed a monopo-
lar spindle phenotype (Figure 3A). Interestingly, and differ-
entiating these latter two conditions, treatment with the
triple combination increased the percentage of cells in
mitosis, which resulted in a significant increase in the
absolute number of monopolar spindles (0, 0, 8 and 19
aberrant spindles per 100 cells, for the control, PD, F and
PDF, respectively (P=0.01 for the F vs. PDF comparison)
(Figure 3A). These results were confirmed in vivo by
immunohistochemistry, since no aberrant monopolar
spindles were found in the control and PD-treated tumors,
while F and PDF displayed an average of 6 and 11
monopolar spindles per field (P=0.008 for the F vs. PDF
comparison; Figure 3B).
PDF causes cell cycle arrest in G2/M phases and
specifically induces apoptosis in cells arrested in 
proliferative phases
The increase in mitotic cells observed with the triple
combination was intriguing, and therefore its specific
effect on the cell cycle profile of treated tumor cells was
studied (Figure 4A). To check whether there was a partic-
ular susceptibility to apoptosis in cells at certain phases of
the cell cycle, simultaneous staining with Draq5 and
Annexin-V was performed (Figure 4B). The treatment
with filanesib in monotherapy arrested cells in the prolif-
erative phases of the cell cycle, with 49% of cells in syn-
thesis (S) and gap 2 mitosis (G2-M) phases compared with
36% in control cells (two-tailed Student's t-test from three
independent experiments P=0.03). The PDF triple combi-
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Figure 5. Role of the increase and activation of the proapoptotic protein BAX on the anti-myeloma efficacy of F and PDF treatments. (A) Cell viability of a panel of
MM cell lines incubated with increasing concentrations of F for 48h and analyzed by MTT assay. Data are expressed as a percentage of control values. B) Western
blot analysis of basal levels of six BCL-2 family members (BCL-2, BCL-XL, MCL-1, BAX, BAK, BAD) studied in the same MM cell lines. C) Expression levels for BAX were
determined by densitometry analysis of bands (using ImageJ software) and relative to those of b-ACTIN. Relation between the basal levels of BAX protein and drug
sensitivity to F was calculated with respect to IC50 for 48h. Statistical analysis was performed with the Mann-Whitney U test. D) Immunoblot of MM.1S cells 24h and
48h after transfection with BAX-specific siRNA. Nontransfected cells (NT) were also analyzed for comparison. 24h after siRNA transfection, cells were treated with
either filanesib (F) or bortezomib (B) for an additional 24h, and apoptosis was assessed by Annexin-V+ cells and evaluated by flow cytometry. E) MM.1S cells were
treated for 12-48h with 10 nM F, and expression levels of MCL-1 and BAX in the mitochondrial and cytosolic fractions were analyzed by western blot. COX IV and
GAPDH expression were used as loading controls for mitochondrial and cytosolic, respectively. F & G) Immunoblot of total (F), mitochondrial and cytosolic (G) extracts
from MM.1S cells treated for 12-48h with the vehicle (control=C), PD, F or PDF for 48h. The expression of COX IV and GAPDH proteins were used as mitochondrial
and cytosolic loading controls, respectively. H) Analysis of mitochondrial membrane potential in MM.1S cells treated with different conditions as assessed by flow
cytometry after TMRE staining. I) Immunohistochemical staining of BAX in tumors from mice treated for two days under the indicated conditions. Bar = 20 mm. In
Figure E, “BAX over” indicates overexposure of the film to better visualize mild changes in the levels of this protein; “p18 BAX” indicates the proapoptotic 18 kDa BAX






nation did not show much difference in this regard com-
pared with filanesib alone, with 44% of cells in G2-M
arrest (Figure 4A). However, treatment with filanesib
specifically induced apoptosis of cells in G2-M phases
with 58% of them being apoptotic compared with only
33% in non-proliferating phases (Figure 4B,C). This fact
was significantly enhanced in the triple combination as
most apoptotic cells (88%) were seen to be in proliferative
phases (G2 or M) (Figure 4B,C). In order to confirm these
findings, various cell cycle markers were biochemically
analyzed. MM.1S cells treated with filanesib and the triple
combination showed an accumulation of CYCLIN B1 lev-
els at 12h and 24h as shown by western blot, this being
indicative of the activation of the spindle assembly check-
point (SAC),28 which correlated with the percentage of
cells arrested in G2-M phases. In contrast to treatment
with filanesib, CYCLIN B1 levels rapidly decreased after
48h in the PDF combination, possibly indicating an
attempt of the cells to exit from mitosis.29,30 However, they
proved unable to do so, as after 48h cells treated with PDF
died in mitosis via apoptosis, as shown by an increase in
phosphorylated histone H3 protein levels, a marker of
mitotic cells,31 and PARP cleavage and degradation32 (Figure
4D). 
The increase in apoptotic induction was confirmed by
Annexin-V/IP staining, as treatment of MM.1S with both
PD and filanesib for 48h induced an increase of Annexin-
V-positive cells (23% and 56%, respectively) compared
with the control (5%), and this effect was much greater
with the triple combination (70% apoptosis; Figure 4E). In
the same manner, the TUNEL assay of treated tumors
revealed a significant increase in apoptotic cells in the
triple combination compared with filanesib or PD alone
(Figure 4F). 
Anti-myeloma efficacy of filanesib in monotherapy
depends on the levels of both the anti-apoptotic 
protein MCL-1 and the proapoptotic protein BAX
To gain insight into the mechanism underlying the
enhanced apoptotic response in dividing cells with PDF
treatment, key molecular features associated with sensi-
tivity to filanesib alone were investigated. A dose
response to filanesib at 48h in 11 cell lines showed that,
although all of them were sensitive to this agent, some cell
lines were more sensitive to filanesib treatment, with
almost no viable cells at 2.5 nM (Figure 5A). Other cells,
however, had higher IC50 values and 30-50% of cells
remained viable even at higher doses of the drug (Figure
5A). Given that the sensitivity to filanesib has previously
been correlated with levels of MCL-1, the basal expression
of six representative BCL-2 family members was evaluat-
ed in the same panel of MM cell lines showing different
patterns of expression (Figure 5B). No correlation was
observed between MCL-1 expression and filanesib sensi-
tivity. However, the sensitivity to filanesib showed a
direct correlation with basal expression levels of BAX, as
shown in Figure 5C (P<0.05), whereby cell lines with
higher basal BAX levels were particularly sensitive to this
agent. In contrast, no correlation was observed between
BAX expression and sensitivity to the proteasome
inhibitor bortezomib, which we used here as a control
(Online Supplementary Figure S5). To confirm the role of
BAX in filanesib-induced cell death, MM.1S cells were
transfected with BAX-specific siRNA. BAX knockdown
induced resistance to filanesib treatment, reducing the
number of apoptotic cells by half (Figure 5D). A similar
effect related to BAX levels was observed in OPM-2 cells
(data not shown).
Moreover, subcellular fractionation studies indicated
that treatment with filanesib triggered the translocation of
BAX from the cytoplasm to the mitochondria, where it
was cleaved into the very potent proapoptotic 18 kDa
fragment33 (Figure 5E). Simultaneously, the levels of the
prosurvival protein MCL-1 also decreased in both subcel-
lular compartments (Figure 5E). These findings suggest the
potential importance of the modulation of both BAX and
MCL-1 protein levels in filanesib-induced apoptosis. 
The PDF triple combination induces augmented 
expression and activation of BAX protein 
Interestingly, and unlike filanesib alone, MCL-1 levels
were not significantly affected after treatment with PDF.
In contrast, two events were clearly potentiated in the
triple combination compared with filanesib alone: first,
PDF induced the expression of total BAX levels in vitro
(Figure 5F), and second, PDF enhanced the presence of this
protein in the mitochondria, where it exerts its apoptotic
activity (Figure 5G). This event led to the permeabilization
of the external mitochondrial membrane, resulting in the
release of the apoptogenic factor CYTOCHROME C into
the cytosol (Figure 5G), and an associated decrease in
mitochondrial membrane potential, as observed by flow
cytometry with tetramethylrhodamine, ethyl ester
(TMRE; Figure 5H). Finally, in vivo experiments confirmed
the PDF-induced BAX upregulation (Figure 5I). 
Discussion
MM remains an incurable disease in most patients34 and
there is an urgent need for novel drugs to improve this sit-
uation. In the work herein, we have preclinically evaluat-
ed the combination of various IMiDs together with dex-
amethasone and filanesib, a novel KSP inhibitor that par-
ticularly affects dividing cells and depends on the survival
protein MCL-1, which is essential for MM cell endur-
ance.13,14 This novel therapeutic agent has already demon-
strated an anti-myeloma effect with dexamethasone,7 and
is currently being explored in combination with protea-
some inhibitors.35 Preliminary data have demonstrated
synergy of filanesib with pomalidomide in a mouse
xenograft model,17 and our in vitro, ex vivo and, notably, in
vivo results clearly confirm this effect and provide evidence
of the benefit of the addition of dexamethasone. This
strong synergistic effect was confirmed in several MM cell
lines, even in the presence of stromal cells. The potency of
the combination with pomalidomide was shown to be
better than those including thalidomide or lenalidomide,
however, one limitation of the present study is that the
advantages bestowed by PDF over TDF or LDF was only
demonstrated in one cell line, that of MM.1S, particularly
in the in vivomodel. Nevertheless, taking into account that
pomalidomide and dexamethasone is currently consid-
ered a backbone for combinations we decided to elaborate
on this particular combination.
Since filanesib is an agent designed to interfere with the
mechanisms of cell division, it is reasonable to think that
it might be particularly effective in actively dividing cells.
In line with this, the in vivo effect of the triple combination
was particularly potent in mice bearing large tumors in the
S. Hernández-García et al.
2122 haematologica | 2017; 102(12)
exponential phase of growth. Interestingly, this combina-
tion resulted in an extended survival of almost two
months, on average, in these end-stage mice. Analysis of
the gene expression profile of both MM cells and PDF-
treated tumors showed a substantial proportion of upreg-
ulated genes to be involved in the centrosome separation
(NEK2), control of spindle assembly checkpoint (CCNB1,
CCNB2) and entry into mitosis (CDC25 C and CDC25 B),
implying that the triple combination significantly alters
mitotic processes. Recently, the overexpression of CCNB2
was associated with an acceleration in centrosome separa-
tion.36 Based on these data, the antimyeloma effect of the
triplet could be due to an increased mitosis and an
increased monopolar spindle formation. In order to inves-
tigate this hypothesis, the phenotype of cells in metaphase
was evaluated by immunohistochemistry. The triple com-
bination induced an increase in the frequency of cells with
an aberrant monopolar spindle phenotype compared with
filanesib monotherapy. Accordingly, we demonstrated
that the PDF combination generated the same degree of
G2-M arrest as did filanesib alone, but the combination
provoked a substantially more specific apoptosis of these
cells when arrested in proliferative phases. A delicate bal-
ance between pro-apoptotic and anti-apoptotic members
of the BCL-2 family and their subcellular localization gen-
erally determines the fate of proliferative cells treated with
anti-mitotic agents.37-40 In particular, it has been reported
that apoptosis is enhanced by the activation of BAX in
cancer cells using other KSP inhibitors.41,42 Accordingly,
silencing BAX prompted cell survival under filanesib treat-
ment in monotherapy. In line with this, PDF treatment
induced increased apoptosis in proliferative phases that
was associated with a significantly higher expression of
the proapoptotic BAX protein, promoting its activation. In
parallel with these results, the tumors of mice treated with
PDF also showed higher immunoreactivity for BAX.
Moreover, we detected a release of the apoptogenic factor
CYTOCHROME C into the cytosol, possibly due to per-
meabilization of the mitochondrial membrane induced by
BAX. These experiments suggest that the expression lev-
els and activation of BAX are crucial in determining the
fate of MM cells treated with PDF. 
In conclusion, we report the strong synergy of the PDF
triple combination in vitro and especially in vivo in preclin-
ical models of MM. The activity of PDF relies on the
induction of monopolar spindles and arrest in mitosis,
characterized by primary activation of SAC; increased
apoptosis in these mitosis-arrested cells is characterized
by the increased expression and activation of BAX, which
could be a useful predictive biomarker of response to PDF
in MM. These results support the phase II clinical trial
POMDEFIL, which is currently being conducted by the
Spanish MM group to evaluate this combination in refrac-
tory MM patients.
Funding
This work was funded in part by Array BioPharma, by the
Spanish ISCIII-FIS (PI 15/0067 and PI 15/2156) and FEDER,
the Spanish RTICC (RD12/0036/0058), Spanish Association
Against Cancer (AECC, GCB120981SAN) and the Regional
Council of Castilla y León (GRS 1029/A/14, GRS 1175/A/15
and FIC335U14). 
Acknowledgments
The authors thank Phil Mason for his help in reviewing the
English language of our manuscript.
Filanesib, pomalidomide and dexamethasone in MM
haematologica | 2017; 102(12) 2123
References
1. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of
progression and survival in multiple myelo-
ma relapsing after therapy with IMiDs and
bortezomib: a multi-center international
myeloma working group study. Leukemia.
2012;26(1):149-157. 
2. Ocio EM, Richardson PG, Rajkumar SV, et
al. New drugs and novel mecha-nisms of
action in multiple myeloma in 2013: a
report from the International Myeloma
Working Group (IMWG). Leukemia. 2014;
28(3):525-542. 
3. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J,
Barlogie B, Shaughnessy J,Jr. Cyclin D dys-
regulation: an early and unifying pathogen-
ic event in multiple mye-loma. Blood. 2005;
106(1):296-303. 
4. Niesvizky R, Lentzsch S, Badros AZ, et al.
A phase I study of PD 0332991: complete
CDK4/6 inhibition and tumor response in
sequential combination with bortezomib
and dexamethasone for relapsed and
refractory multiple myeloma. ASH Annual
Meeting Abstracts. 2010; 116(21):860. 
5. Rosenthal A, Kumar S, Hofmeister C, et al.
A phase Ib study of the combination of the
aurora kinase inhibitor alisertib (MLN8237)
and bortezomib in relapsed multiple
myeloma. Br J Haematol. 2016; 174(2):323-
325. 
6. Kollareddy M, Zheleva D, Dzubak P,
Brahmkshatriya PS, Lepsik M, Hajduch M.
Aurora kinase inhibitors: progress towards
the clinic. Invest New Drugs. 2012;
30(6):2411-2432. 
7. Lonial S, Shah JJ, Zonder J, Bensinger, W.I.,
Cohen AD, Kaufman JL, et al. Prolonged
survival and improved response rates with
ARRY-520 in relapsed/refractory multiple
myeloma (RRMM) patients with low α-1
acid glycoprotein (AAG) levels: results
from a phase 2 study. Blood. 2013;
122(21):285. 
8. Ocio EM, Mitsiades CS, Orlowski RZ,
Anderson KC. Future agents and treatment
directions in multiple myeloma. Expert Rev
Hematol. 2014;7(1):127-141. 
9. Jackson JR, Patrick DR, Dar MM, Huang
PS. Targeted anti-mitotic therapies: can we
improve on tubulin agents? Nat Rev
Cancer. 2007;7(2):107-117. 
10. Blangy A, Lane HA, d'Herin P, Harper M,
Kress M, Nigg EA. Phosphoryla-tion by
p34cdc2 regulates spindle association of
human Eg5, a kinesin-related motor essen-
tial for bipolar spindle formation in vivo.
Cell. 1995;83(7):1159-1169. 
11. Stern BM, Murray AW. Lack of tension at
kinetochores activates the spindle check-
point in budding yeast. Curr Biol. 2001;
11(18):1462-1467. 
12. Tunquist BJ, Woessner RD, Walker DH.
Mcl-1 stability determines mitotic cell fate
of human multiple myeloma tumor cells
treated with the kinesin spindle protein
inhibitor ARRY-520. Mol Cancer Ther.
2010;9(7):2046-2056. 
13. Peperzak V, Vikstrom I, Walker J, et al. Mcl-
1 is essential for the survival of plasma
cells. Nat Immunol. 2013;14(3):290-297. 
14. Zhang B, Gojo I, Fenton RG. Myeloid cell
factor-1 is a critical survival factor for mul-
tiple myeloma. Blood. 2002;99(6):1885-93. 
15. San Miguel J, Weisel K, Moreau P, et al.
Pomalidomide plus low-dose dex-ametha-
sone versus high-dose dexamethasone
alone for patients with relapsed and refrac-
tory multiple myeloma (MM-003): a ran-
domised, open-label, phase 3 trial. Lancet
Oncol. 2013;14(11):1055-1066. 
16. Dimopoulos MA, Palumbo A, Corradini P,
et al. An updated analysis of the STRATUS
trial (MM-010): safety and efficacy of
pomalidomide plus low-dose dexametha-
sone (POM + LoDEX) in patients (Pts) with
relapsed/refractory multiple myeloma
(RRMM). Blood. 2015;126(23):4225. 
17. Humphries MJ, Anderson D, Williams L,
Rieger R, Tunquist B, Walker D. ARRY-520
combined with pomalidomide displays
enhanced anti-tumor activity in preclinical
models of multiple myeloma. Blood.
2013;122(21):3167. 
18. Paino T, Garcia-Gomez A, Gonzalez-
Mendez L, et al. The novel pan-PIM kinase
inhibitor, PIM447, displays dual antimyelo-
ma and bone-protective effects, and
potently synergizes with current standards
of care. Clin Cancer Res. 2017;23(1):225-
238.
19. Herrero AB, San Miguel J, Gutierrez NC.
Deregulation of DNA double-strand break
repair in multiple myeloma: implications
for genome stability. PLoS One.
2015;10(3):e0121581. 
20. Garcia-Gomez A, Quwaider D, Canavese
M, et al. Preclinical activity of the oral pro-
teasome inhibitor MLN9708 in Myeloma
bone disease. Clin Cancer Res.
2014;20(6):1542-1554. 
21. Ocio EM, Maiso P, Chen X, et al. Zalypsis:
a novel marine-derived com-pound with
potent antimyeloma activity that reveals
high sensitivity of malignant plasma cells to
DNA double-strand breaks. Blood.
2009;113(16):3781-3791. 
22. Paino T, Sarasquete ME, Paiva B, et al.
Phenotypic, genomic and functional char-
acterization reveals no differences between
CD138++ and CD138low sub-populations
in multiple myeloma cell lines. PLoS One.
2014;9(3):e92378. 
23. Chou TC. Drug combination studies and
their synergy quantification using the
Chou-Talalay method. Cancer Res. 2010;
70(2):440-446. 
24. Maiso P, Carvajal-Vergara X, Ocio EM, et
al. The histone deacetylase in-hibitor
LBH589 is a potent antimyeloma agent that
overcomes drug resistance. Cancer Res.
2006;66(11):5781-5789. 
25. Ocio EM, Vilanova D, Atadja P, et al. In
vitro and in vivo rationale for the triple
combination of panobinostat (LBH589) and
dexamethasone with either bortezomib or
lenalidomide in multiple myeloma.
Haematologica. 2010;95(5):794-803. 
26. Irizarry RA, Bolstad BM, Collin F, Cope
LM, Hobbs B, Speed TP. Summa-ries of
Affymetrix GeneChip probe level data.
Nucleic Acids Res. 2003;31(4):e15. 
27. Tusher VG, Tibshirani R, Chu G.
Significance analysis of microarrays ap-
plied to the ionizing radiation response.
Proc Natl Acad Sci USA. 2001;98(9):5116-
5121. 
28. Musacchio A, Salmon ED. The spindle-
assembly checkpoint in space and time.
Nat Rev Mol Cell Biol. 2007;8(5):379-393. 
29. Pines J. Cubism and the cell cycle: the
many faces of the APC/C. Nat Rev Mol
Cell Biol. 2011;12(7):427-438. 
30. Murray A. Cyclin ubiquitination: the
destructive end of mitosis. Cell.
1995;81(2):149-152. 
31. Schimming TT, Grabellus F, Roner M, et al.
pHH3 immunostaining improves interob-
server agreement of mitotic index in thin
melanomas. Am J Dermatopa-thol.
2012;34(3):266-269. 
32. Kaufmann SH, Desnoyers S, Ottaviano Y,
Davidson NE, Poirier GG. Spe-cific prote-
olytic cleavage of poly(ADP-ribose) poly-
merase: an early marker of chemotherapy-
induced apoptosis. Cancer Res.
1993;53(17):3976-3985. 
33. Cao X, Deng X, May W. Cleavage of Bax to
p18 Bax accelerates stress-induced apopto-
sis, and a cathepsin-like protease may rap-
idly degrade p18 Bax. Blood.
2003;102(7):2605-2614. 
34. Barlogie B, Mitchell A, van Rhee F, Epstein
J, Morgan GJ, Crowley J. Curing myeloma
at last: defining criteria and providing the
evidence. Blood. 2014;124(20):3043-3051. 
35. Shah JJ, Thomas S, Weber DM, Wang M,
Orlowski R. Novel kinesin spindle protein
inhibitor ARRY–520 + carfilzomib(Car) in
patients with relapsed and/or refractory
multiple myeloma (RRMM).
Haematologica. 2013;98(S1):Abstract-S579. 
36. Nam HJ, van Deursen JM. Cyclin B2 and
p53 control proper timing of cen-trosome
separation. Nat Cell Biol. 2014;16(6):538-
549. 
37. Ferlini C, Cicchillitti L, Raspaglio G, et al.
Paclitaxel directly binds to Bcl-2 and func-
tionally mimics activity of Nur77. Cancer
Res. 2009;69(17):6906-6914. 
38. Vijapurkar U, Wang W, Herbst R.
Potentiation of kinesin spindle protein in-
hibitor-induced cell death by modulation of
mitochondrial and death receptor apoptotic
pathways. Cancer Res. 2007;67(1):237-245. 
39. Haschka MD, Soratroi C, Kirschnek S, et al.
The NOXA-MCL1-BIM axis de-fines lifes-
pan on extended mitotic arrest. Nat
Commun. 2015;6:6891. 
40. Wang P, Lindsay J, Owens TW, et al.
Phosphorylation of the proapoptotic BH3-
only protein bid primes mitochondria for
apoptosis during mitotic arrest. Cell Rep.
2014;7(3):661-671. 
41. Tao W, South VJ, Zhang Y, et al. Induction
of apoptosis by an inhibitor of the mitotic
kinesin KSP requires both activation of the
spindle assembly check-point and mitotic
slippage. Cancer Cell. 2005;8(1):49-59. 
42. Tao W, South VJ, Diehl RE, et al. An
inhibitor of the kinesin spindle protein acti-
vates the intrinsic apoptotic pathway inde-
pendently of p53 and de novo pro-tein syn-
thesis. Mol Cell Biol. 2007;27(2):689-698. 
S. Hernández-García et al.
2124 haematologica | 2017; 102(12)
